CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on April 30, 2020
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
April 30, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Corbus Pharmaceuticals Holdings, Inc. (the “Company”) |
Registration Statement on Form S-3, as amended (File No. 333-237588)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on May 1, 2020, or as soon as practicable thereafter.
Please call Michael J. Lerner of Lowenstein Sandler LLP at (973) 597-6394 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
April 30, 2020
Page 2
| Very truly yours, | ||
| CORBUS PHARMACEUTICALS | ||
| HOLDINGS, INC. | ||
| By: | /s/ Sean Moran | |
| Name: | Sean Moran | |
| Title: | Chief Financial Officer | |
| -2- |